MC2 Evaluation and Management of Adrenal Neoplasias

Program: Master Clinician Sessions
Clinical Session
Sunday, April 3, 2016: 4:45 PM-5:45 PM
Hall B2 (BCEC)
Moderator:
Richard A. Feelders, MD PhD, Erasmus Medical Center, Rotterdam, Netherlands
Experts:
Hirotaka Shibata, MD, PhD, Oita University, Yufu-city, Japan and Ana Claudia Latronico, MD, PhD, Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil., ,

Disclosures:
AL: Advisory Group Member, Ipsen, Advisory Group Member, EMD Serono, Editor, Up To Date, Investigator, Novartis Pharmaceuticals, Investigator, Strongbridge. MEM: own stock, Amgen, Investigator, Bayer, Inc., Investigator, Ipsen, Advisory Group Member, Jansen Pharmaceuticals, Advisory Group Member, Johnson &Johnson, Investigator, Novartis Pharmaceuticals, Investigator, Novo Nordisk, Advisory Group Member, Merck & Co., Advisory Group Member, Pfizer, Inc.. Nothing to Disclose: RAF, AV, MAH Disclosure Not Provided: HS, ACL, GDH

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire